122 related articles for article (PubMed ID: 10365100)
1. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer.
Koivisto PA; Rantala I
J Pathol; 1999 Jan; 187(2):237-41. PubMed ID: 10365100
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma.
Koivisto PA; Helin HJ
J Pathol; 1999 Oct; 189(2):219-23. PubMed ID: 10547578
[TBL] [Abstract][Full Text] [Related]
4. In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
Visakorpi T; Hyytinen E; Koivisto P; Tanner M; Keinänen R; Palmberg C; Palotie A; Tammela T; Isola J; Kallioniemi OP
Nat Genet; 1995 Apr; 9(4):401-6. PubMed ID: 7795646
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
[TBL] [Abstract][Full Text] [Related]
8. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.
Brown RS; Edwards J; Dogan A; Payne H; Harland SJ; Bartlett JM; Masters JR
J Pathol; 2002 Oct; 198(2):237-44. PubMed ID: 12237884
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer.
Haapala K; Kuukasjärvi T; Hyytinen E; Rantala I; Helin HJ; Koivisto PA
Hum Pathol; 2007 Mar; 38(3):474-8. PubMed ID: 17217995
[TBL] [Abstract][Full Text] [Related]
10. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor gene mutations in hormone-refractory prostate cancer.
Wallén MJ; Linja M; Kaartinen K; Schleutker J; Visakorpi T
J Pathol; 1999 Dec; 189(4):559-63. PubMed ID: 10629558
[TBL] [Abstract][Full Text] [Related]
12. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.
Koivisto P; Hyytinen E; Palmberg C; Tammela T; Visakorpi T; Isola J; Kallioniemi OP
Am J Pathol; 1995 Dec; 147(6):1608-14. PubMed ID: 7495286
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
14. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer.
Koivisto P; Visakorpi T; Rantala I; Isola J
J Pathol; 1997 Sep; 183(1):51-6. PubMed ID: 9370947
[TBL] [Abstract][Full Text] [Related]
15. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
16. Alterations of androgen receptor in prostate cancer.
Linja MJ; Visakorpi T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):255-64. PubMed ID: 15663988
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
[TBL] [Abstract][Full Text] [Related]
19. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia.
Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J
Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
